S/N 10/665,990 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael A. Apicella et al.

Art Unit :1645

Serial No.: 10/665,990

Examiner :Padmavathi Baskar

Filed

: September 19, 2003

Docket

:17023.031US1

Title

: VACCINE AND COMPOSITIONS FOR THE PREVENTION AND

TREATMENT OF NEISSERIAL INFECTIONS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

An Information Disclosure Statement filing fee of \$180.00 is submitted herewith. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

> Respectfully submitted, Michael A. Apicella et al. By their Representatives. Viksnins Harris & Padys PLLP P.O. Box 111098 St. Paul, MN 55111

952 876-4094

Date October 04, 2006

Peter, Reg. No. 44.894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Ameridment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this _____ day of October, 2006.

Name Kutw Mal

Substitute for form 1449A/PTO and/or 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known		
	Application Number	10/665,990	
	Filing Date	September 19, 2003	
	First Named Inventor	Michael A. Apicella	
	Group Art Unit	1645	
	Examiner Name	Padmavathi Baskar	
Sheet 1 of 1	Attorney Docket No: 17023.031US1		

US PATENT DOCUMENTS				
Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document	
	2003/0100071	May 29, 2003	Apicella et al.	

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)	
		·		

	OTHER DOCUMENTS NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u> , page(s) and (date).		
	International Search Report for International Application Serial Number PCT/US02/02881, (2003).		
	International Search Report for International Application Serial Number PCT/US2004/022708, (2004).		
	Barritt et al., "Antigenic and structural differences among six proteins II expressed by a single strain of <i>Neisseria gonorrhoeae</i> ", <u>Infect Immun.</u> , <u>55(9)</u> , 2026-2031 (1987).		
	Cohen et al., "Human experimentation with <i>Neisseria gonorrhoeae</i> : Progress and goals", <u>J</u> Infect Dis., 179, Suppl 2, S375-S379 (1999).		
	Densen, "Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae", Clin Microbiol Rev., 2, Suppl:S11-17 (1989).		
·	Edwards et al., "Neisseria gonorrhoeae elicits membrane ruffling and cytoskeletal rearrangements upon infection of primary human endocervical and ectocervical cells", Infect Immun., 68(9), 5354-5363 (2000).		
	Edwards et al., "Neisseria gonorrhoeae PLD directly interacts with Akt kinase upon infection of primary, human, cervical epithelial cells", Cell Microbiol., 8(8), 1253-1271 (2006).		
	Thankavel et al., "Localization of a domain in the FimH adhesin of <i>Escherichia coli</i> type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection", <u>J Clin Invest.</u> , 100(5), 1123-1136 (1997).		
	Zhang et al., "Enhanced immunogenicity of a genetic chimeric protein consisting of two virulence antigens of <i>Streptococcus mutans</i> and protection against infection", <u>Infect Immun.</u> , 70(12), 6779-6787 (2002).		